ReviewMolecules (Basel, Switzerland)2022
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.Frontiers in psychiatry · 2024Pooled it
- Moving beyond 5-HTPsychopharmacology · 2026Article
- Evaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention.Veterinary sciences · 2026Article
- Understanding treatment expectations toward emerging therapies in veterinary medicine: the role of knowledge, attitudes, and beliefs toward psychedelic-assisted interventions.Frontiers in veterinary science · 2026Article
- Review
- Review of Selected 2-Phenylethylamine Derivatives and Opioids, Systematic Review of Their Effects on Psychomotor Abilities and Driving Performance: Psychopharmacology in the Context of Road Safety.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Preliminary Findings on Low-Dose 1cp-LSD for Canine Anxiety: Exploring the Role of Owner Neuroticism and Psychopathology.Veterinary sciences · 2025Article
- Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study.Veterinary medicine and science · 2025Article
- Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration.Translational psychiatry · 2025Article
- Review
- Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.Cancer medicine · 2025Review
- Psychedelics as moral bioenhancers: Protocol for a scoping review of ethical arguments for and against.Wellcome open research · 2025Article
- Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.Pharmacological reports : PR · 2024Review
- Single-dose 1cp-LSD administration for canine anxiety: a pilot study.Veterinary research communications · 2024Article
- 5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics.ACS pharmacology & translational science · 2024Article
- Behavior, antioxidant, and metabolomics effects ofFood science & nutrition · 2024Article
- Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?Frontiers in human neuroscience · 2024Article
- Cardiovascular safety of psychedelic medicine: current status and future directions.Pharmacological reports : PR · 2023Review
- Review
- Production, Characterization, and In Vitro and In Vivo Studies of Nanoemulsions Containing St. John's Wort Plant Constituents and Their Potential for the Treatment of Depression.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The word "psychedelic" (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.